Cost effectiveness of treatments for amyotrophic lateral sclerosis: A review of the literature

PharmacoEconomics

Volumn 20, Issue 6, 2002, Pages 367-387

  Ginsberg, G ^a   Lowe, S ^b  

^a MINISTRY OF HEALTH   (Israel)

^b Health and Disabilities Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; LAMOTRIGINE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SURVIVAL;

EID: 0036290110     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220060-00002     Document Type: Review

References (148)

1. Nutritional management on amyotrophic lateral sclerosis: A worldwide perspective
2. Human mecasermin: A review of its use in amyotrophic lateral sclerosis
3. Riluzole for motor neurone disease
4. How to improve the diagnostic process
5. Risk factors in amyotrophic lateral sclerosis
6. The ALS patient care database: Goals, design, and early results
7. Epidemiological survey of amyotrophic lateral sclerosis in the province of reggio Emilia, Italy: Influence of environmental exposure to lead
8. Incidence and prevalence of ALS in Ireland, 1995-1997: A population-based study
9. Comprehensive management of amyotrophic lateral sclerosis
10. The prognosis of adult-onset motor neuron disease: A prospective study based on the Scottish Motor Neuron Disease Register
11. Natural history of amyotrophic lateral sclerosis in a database population: Validation of a scoring system and a model for survival prediction
12. Amyotrophic lateral sclerosis: A study of its presentation and prognosis
13. Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia
14. Amyotrophic lateral sclerosis. Part 1. Clinical features, pathology, and ethical issues in management
15. Respiratory sysytem in amyotropic lateral sclerosis
16. The natural history of amyotrophic lateral sclerosis: A study of its presentations and prognosis
17. Clinical statistics in 515 fatal cases of motor neuron disease: Determinants of course
18. Genetics of familial ALS and consequences for diagnosis
19. Epidemiology of amyotrophic lateral sclerosis: A case-controlled comparison based on ALSD deaths
20. Motor neuron disease in Hong Kong Chinese: Epidemiology and clinical picture
21. Clinical epidemiology of amyotrophic lateral sclerosis
22. Adult onset motor neuron disease: Worldwide mortality, incidence and distribution since 1950
23. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state
24. The Scottish motor neuron disease register: A perspective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989
25. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas 1985-1988
26. MND risk factors: An epidemiological study in the North west of England
27. Changes in the incidence of amyotrophic lateral sclerosis in Israel
28. Differential features of motor neuron disease mortality in Spain
29. Projected neurodegenerative disease mortality in the United States, 1990-2040
30. Amyotrophic lateral sclerosis: Practical treatment recommendations
31. The effects of riluzole in amyotrophic lateral sclerosis: A study with cortical stimulation
32. Increasing trend of ALS in France and elsewhere: Are the changes real
33. Population-based case-control study of amyotropic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption
34. Population-based case-control study of amyotropic lateral sclerosis in western Washington State. II. Diet
35. Mortality from amyotropic lateral sclerosis, other chronic disorders, and electric shocks among utility workers
36. A case-control study of amyotrophic lateral sclerosis
37. Neurodegenerative diseases: Occupational occurence and potential risk factors, 1982 through 1991
38. Electrical occupations and neurodegenerative disease: Analysis of U.S. Mortality Data
39. Conceptual approach to diagnostic delay in ALS: A United States perspective
40. The Netherlands ALS Consortium. Amyotrophic lateral sclerosis: Mortality risk during the course of the disease and prognostic factors
41. Current treatment pathways in ALS: A South American perspective
42. ISIS Survey: An international study on the diagnostic process and its implications in amytrophic lateral sclerosis
43. Current treatment pathways in ALS: A European perspective
44. Clinical update
45. The diagnostic process in ALS
46. What are the implications of early diagnosis? Maintaining optimal health as long as possible
47. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
48. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS
49. A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience
50. Diagnostic challenges in ALS
51. Simplifying the approach: What can we do?
52. An algorithm for ALS diagnosis and management
53. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection
54. Nutritional status of patients with amyotrophic lateral sclerosis: Relation to the proximity of death
55. Classification and clinical features of amyotrophic lateral sclerosis
56. Prognostic indicators of survival in ALS: ALS CNTF Treatment Study Group
57. Amyotrophic lateral sclerosis: Its natural history
58. A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group
59. Spirometry in amyotrophic lateral sclerosis
60. Nutritional status is a prognostic factor for survival in ALS patients
61. Motor unit number estimate-based rates of progression of ALS predict patient survival
62. Management of ALS: Nutritional Care
63. Treatment of amyotrophic lateral sclerosis
64. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
65. A confirmatory dose-ranging study of riluzole in ALS
66. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: Double-blind placebo-controlled study in Japan
67. Riluzole and amotrophic lateral sclerosis
68. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review)
69. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis
70. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis
71. Riluzole restores impaired intracortical inhibition in patients with ALS
72. Riluzole has no acute effect on motor unit parameters in ALS
73. Author's reply to riluzole
74. The administration of guanidine in amyotrophic lateral sclerosis
75. Open label study of riluzole for the treatment of amyotrophic lateral sclerosis
76. Blood pressure elevations in riluzole-treated patients with ALS
77. Open-label trial of riluzole 50mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
78. Glutamate antagonists in amyotrophic lateral sclerosis: A review of their therapeutic potential
79. A placebo-controlled trial of insulin-like growth factor-1 in ALS: European ALS/IGF-1 Study Group
80. The role of insulin-like growth factors in the central nervous system
81. The role of insulin-like growth factors in the central nervous system
82. Measurement of health-related quality of life in patients with amyorophic lateral sclerosis in clinical thais of new therapies
83. Effects of recombinant human insulin-like growth factor I on progression of ALS: A placebo controlled study
84. Potential use of gabapentin and lamotrigine
85. The natural history and the effects of gabapentin in amyotrophic lateral sclerosis
86. Use of composite scores (megascores) to measure deficit in ALS
87. The natural history of motomeuron loss in amyotrophic lateral sclerosis
88. Placebo-controlled study of gabapentin in patients with amyotrophic lateral sclerosis
89. Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine
90. An attempt to inhibit the course of amyotrophic lateral sclerosis (ALS) by suppressor factor
91. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes
92. Safety and factors related to survival after percutaneous endoscopic gastronomy in ALS
93. ALS: Predictors for prolongation of life by noninvasive respiratory aids
94. Effect of noninvasive positive-pressure ventilation on survival in ALS
95. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers
96. Home mechanical ventilation for amyotrophic lateral sclerosis: Nasal compared to tracheostomy-intermittent positive pressure ventilation
97. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: Survival rates in a controlled trial
98. BIPAP improves survival and rate of pulmonary function decline in patients with ALS
99. Management of ALS respiratory care
100. Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis
101. Valuation of EuroQOL (EQ-5D) health states in an adult US sample
102. A 12-item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity
103. The European Amyotrophic Lateral Sclerosis Health profile study
104. The ALS-Health profile study: Quality of life of ALS patients and carers in Europe
105. Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis
106. Is the SF-36 suitable for assessing health status of older stroke patients?
107. Health utilities in Alzheimer's disease: A cross-sectional study of patients and caregivers
108. Quality of life assessment in MND: Development of a Social Withdrawal Scale
109. Quality of life in ALS depends on factors other than strength and physical function
110. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide
111. Factors influencing a patient's decision regarding riluzole: An early experience
112. A prospective study of preferences and actual treatment choices in ALS
113. The economic impact of ALS
114. Home ventilation for amyothropic lateral sclerosis patients: Outcomes, costs and patient, family, and physician attitudes
115. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation: Advance care planning and outcomes
116. Disease management: The example of amyotrophic lateral sclerosis
117. Economic burden of amyotrophic lateral sclerosis in the United Kingdom
118. Life support: Realities and dilemmas
119. ALS/MND and the perspective of health economics
120. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis
121. Cost effectiveness of riluzole in amyotrophic lateral sclerosis
122. Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis
123. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
124. A cost-effectiveness analysis of the treatment of end stage renal failure
125. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection
126. Cost-effectiveness analysis of end-stage renal disease treatments
127. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia
128. Cost-effectiveness analysis of transplantation
129. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients
130. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia
131. Validation of a caregiver strain index
132. The Amyotrophic Lateral Sclerosis Functional rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis
133. Performance of the Amyotrophic Lateral Sclerosis Funcional rating Scale (ALSFRS) in multi-center clinical trials
134. A fair approach to discounting future effects: Taking a societal perspective
135. Earlier is better: The benefits of early diagnosis
136. Five Hundred life saving interventions and their cost effectiveness
137. Diminishing marginal utility of health effects
138. Antiglutamate therapy for ALS: Which is the next step?
139. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
140. Global trends in the health-care environment: Economic considerations in making a case for people with amyotrophic lateral sclerosis